Elmer LW, et al. - Researchers presented pooled results from two randomized, double-blind, placebo-controlled, phase III studies of ADS-5102 (amantadine) extended-release capsules for dyskinesia in Parkinson’s disease (PD). The present analyses supported ADS-5102 as an adjunct to levodopa for treating both dyskinesia and OFF time (often referred to as ‘wearing off’, or OFF time) in PD patients with dyskinesia.